June 5, 2019
U.S. Securities and Exchange Commission
Office of the Chief Accountant
100 F Street NE
Washington, DC 20549
Dear Sir/Madam:
We have read the statements under item 4.01 in the Form 8-K dated June 5, 2019 of Generex Biotechnology Corporation (the “Company”) to be filed with the U.S. Securities and Exchange Commission and we agree with such statements therein as related to our firm. We have no basis to, and therefore, do not agree or disagree with the other statements made by the Company in the Form 8-K.
Yours truly,
/MNP LLP
MNP LLP
Chartered Professional Accountants
Licensed Public Accountants